Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Immunocore Limited
Sponsor

Immunocore Limited

United Kingdom 92 Park Drive, Milton, OX14 4RY, United Kingdom

About the sponsor

Immunocore Limited supports clinical research in advanced uveal melanoma and previously treated non-ocular advanced melanoma, with a clear emphasis on T-cell receptor-based immunotherapy and immune checkpoint combinations.

  • HLA-A*0201-restricted treatment approaches
  • Overall survival in advanced melanoma
  • Combination immunotherapy strategies

The sponsor’s oncology portfolio is centered on treatment approaches for advanced melanoma populations with limited therapeutic options, including patients with metastatic disease and those requiring systemic immune-based therapy.

About Specializations

Immunocore Limited runs clinical trials in conditions such as Type 1 diabetes mellitus, Metastatic malignant melanoma, Uveal melanoma, HIV infection, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Type 1 diabetes mellitus

Recruiting

Safety and Pharmacokinetic Dose-Escalation Study of IMC-S118AI and Sodium Chloride in HLA‑A*02:01‑Positive Participants with Type 1 Diabetes

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Immunocore Limited

Metastatic malignant melanoma+1

Recruiting

Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Immunocore Limited

HIV infection

Not recruiting

Study of IMC-M113V for Patients with Chronic HIV Infection Who Are Virologically Suppressed

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bispecific Protein With A High-Affinity T-Cell Receptor Domain Fused To An Antibody Single-Chain Variable Fragment Against Cd3
  • Sponsor:Immunocore Limited

Malignant melanoma

Not recruiting

Study on Tebentafusp and Drug Combination for Patients with Advanced Uveal Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Immunocore Limited

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.